// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Chronic respiratory diseases (CRDs in low- and middle-income countries (LMICs: A scoping review of survey methodologies

nik sherina Hanafi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

An audit of salbutamol use before children are admitted to hospital with acute asthma

Stephanie Cheetham - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Salbutamol

Understanding information needs of patients with asthma in the United Kingdom

Kirstie McClatchey - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

FeNO testing for asthma diagnosis in primary care

Jayne Longstaff - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

A genome-wide association study of asthma-COPD overlap syndrome (ACOS

Catherine John - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Autoimmune sclerosing cholangitis

N/A

Bronchial airway inducible expression and methylation QTL mapping identifies a single nucleotide polymorphism predicting inhaled corticosteroids response heterogeneity

Elise M.A. Slob - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Interaction between VGDF exposure and antioxidant genes on COPD in UK Biobank

Diana van der Plaat - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Rhinovirus & IL33 driven HBEC gene signatures are disease & IL1RL1 polymorphism dependent

Michael Portelli - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?

Nazia Chaudhuri - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Glucocorticoid

Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial

Claudia Valenzuela - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nintedanib

Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial

Kevin R. Flaherty - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nintedanib

Prognostic characteristics in chronic hypersensitivity pneumonitis

Daniel Neville - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Extrinsic allergic alveolitis

N/A

King’s Brief Interstitial Lung Disease (K-BILD questionnaire: content relevance in progressive fibrosing ILD (PF-ILD

Surinder S. Birring - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Consistent effect of nintedanib on reducing FVC decline across interstitial lung diseases (ILDs

Francesco Bonella - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact

Martina Bonifazi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

N/A

Effects of nintedanib on markers of epithelial damage in subjects with IPF: data from the INMARK trial

Gisli Jenkins - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nintedanib

Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial

Eric White - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Nintedanib

Monounsaturated Fatty Acid diet associates less gastrointestinal adverse events of pirfenidone: phase IV clinical trial

Eva Fontanilles - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Nijmegen Breakage Syndrome

Pirfenidone

Validation of 18F-Fluorodeoxyglucose Positron Emission Tomography as a Translational Biomarker to Support the Development of Novel Anti-fibrotic Drug Therapies

Juliana Maynard - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Bleomycin

Pirfenidone in unclassifiable ILD (uILD: subgroup analysis of patients with/without a surgical lung biopsy (SLB

Vincent Cottin - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Pirfenidone

Copyright © 2026. QuantiNova All rights reserved